Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
2 drugs in development
By Therapeutic Area
top 2
R&D Momentum
66/100
Pipeline Velocity
37/100
Trial Completion Rate
96/100
Pipeline Concentration
50/100
Pipeline Freshness
34/100
Strategic Signals
Activity
Last 14 days
Minimum Effective Dose of Ropivacaine 0.5% for Ultrasound-guided Interscalene Block Targeting the C7 Nerve Root in Hand and Forearm Surgery
The Diagnostic and Triage Capacity of Laypeople-large Language Model Collaboration: a National Pretest-posttest Randomized Controlled Experiment in China
A Randomized Trial of Liposomal Bupivacaine, Ropivacaine With Perineural Dexamethasone, and Ropivacaine With Perineural Dexmedetomidine for Adductor Canal Block Combined With IPACK Block in Total Knee Arthroplasty
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)